BTG appoints non-exec director
This article was originally published in Scrip
Executive Summary
BTG, a specialist healthcare company developing and commercializing products targeting critical care, cancer and other disorders, has named Susan Foden a non-executive director of its board – effective 1 March 2015. Dr Foden is currently chair of BerGenBio and Cizzle Biotech, holds non-executive roles with Vectura Group, Evgen and Source Bioscience and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund). Previously Dr Foden has held the positions of investor director with the venture capital firm Merlin Biosciences, CEO of the technology transfer company Cancer Research Campaign Technology, and head of academic liaison at Celltech.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.